SEARCH

SEARCH BY CITATION

Keywords:

  • bipolar disorder;
  • immuno-inflammatory system;
  • neurodevelopment;
  • neurodegenerative hypotheses;
  • schizophrenia

Abstract

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Several lines of evidence point to the key role of neurobiological mechanisms and shared genetic background in schizophrenia and bipolar disorder. For both disorders, neurodevelopmental and neurodegenerative processes have been postulated to be relevant for the pathogenesis as well as dysregulation of immuno-inflammatory pathways. Inflammation is a complex biological response to harmful stimuli and it is mediated by cytokines cascades, cellular immune responses, oxidative factors and hormone regulation. Cytokines, in particular, are supposed to play a critical role in infectious and inflammatory processes, mediating the cross-talk between the brain and the immune system; they also possibly contribute to the development of the central nervous system. From this perspective, even though mixed results have been reported, it seems that both schizophrenia and bipolar disorder are associated with an imbalance in inflammatory cytokines; in fact, some of these could represent biological markers of illness and could be possible targets for pharmacological treatments. In light of these considerations, the purpose of the present paper was to provide a comprehensive and critical review of the existing literature about immunological abnormalities in bipolar disorder with particular attention to the similarities and differences with schizophrenia.

BIPOLAR DISORDER (BD) and schizophrenia are severe disabling disorders, which for several decades have been considered as distinct clinical entities. However, they share common biological features, such as brain changes in cases of long illness duration.[1] Moreover, alterations in inflammatory pathways could lead to a common pathogenetic hypothesis involving immune dysregulation.[2] The sharing of common inflammatory mechanisms does not match with the ‘classical’ binary classification of psychiatric disorders, but instead seems to support the hypothesis of a ‘continuum’ in pathogenetic patterns between BD and schizophrenia.[3-5] Of note, several data indicate that cytokines can be the mediator of metabolic/brain changes associated with clinical symptoms both of schizophrenia and BD.[6]

Cytokines are a family of polypeptides that are essential to the immune system and are crucial systemic mediators of host response to infection, representing a robust marker of infectious and inflammatory conditions.[7] Cytokines are synthesized and secreted by both immune and non-immune cells and their effects are mediated by specific receptors expressed on the surface of target cells. Cytokine receptors are available also in soluble forms and their activity can either enhance or inhibit the activity of cytokines. The action of cytokines is exerted by activation and recruitment of immune cells, increased vascular permeability and blood supply to inflamed tissues. Cytokines are frequently regulated in cascades, where induction of early molecules stimulate the production of later ones.[8] They interact with hypothalamic–pituitary axis (HPA), monoaminergic system (dopamine, serotonin and glutamate) and autonomic system.[9] Examples of cytokines include interleukins (IL), interferons (INF), tumor necrosis factors (TNF), transforming growth factors (TGF) and chemokines. These molecules and their receptors are expressed physiologically in central nervous system (CNS) cells. However, in normal conditions, many cytokines are virtually undetectable in the CNS and, because of their large size, their ability to cross the brain–blood barrier is reduced. Therefore, it has been argued that cytokines could access the CNS through several pathways, including: (i) binding to specific transporters on brain endothelium; (ii) activation of peripheral vagal fibres, which could transmit the signal to deep brain nuclei, such as nucleus of the solitary tract, which has the role of relay station to other brain nuclei; (iii) through leaky areas, such as the circumventricular organs; and (iv) increased permeability of brain–blood barrier.[10, 11] As well as entering from the periphery, cytokines can be secreted directly in the CNS, mainly by astrocytes and microglia.[12-15] Centrally secreted cytokines play a role in modulating neuronal development and plasticity, tissue repair and synaptogenesis[16, 17] or even promoting neural damage after brain insult.[18] Rapid induction and sustained elevation of cytokines in immune and glial cells under inflammatory response play a role in the dysregulation of neural cell homeostasis. This contributes to abnormal neural cell development, cytotoxicity and loss of oligodendrocytes.[19]

Actually, abnormal levels of proinflammatory cytokines and their receptors have been found in peripheral blood and cerebrospinal fluid of schizophrenic patients.[20-22] Recently, studies have focused on the role of cytokines in BD; however, less evidence is present with respect to schizophrenia.[20] In addition, recent studies have clarified the reasons for cytokine dysfunction, and the role of immune polymorphisms and antioxidants, providing alternative views about the pathophysiology of major psychoses.[23]

On the basis of the mentioned data, the present article aims to provide a comprehensive updated overview of the main acquisitions in the field of immuno-inflammatory abnormalities in BD with particular attention to the similarities and differences with schizophrenia.

Methods

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Literature for this overview was identified by searching database sources (Medline, PsycINFO, Isi Web of Knowledge, Medscape) and Cochrane Libraries in two steps. First, a search was carried out identifying articles published related to inflammatory processes in schizophrenia and BD. Specifically, the keywords ‘schizophrenia’ and/or ‘bipolar disorder’ were variably combined with the terms ‘immune system’, ‘inflammation’ and ‘cytokines’. Furthermore, we performed a manual search for relevant articles, examining the reference lists of publications retrieved in the primary search. No restriction criteria were established in relation to study design so that the present review includes researches with different methodologies (e.g. open-label and controlled studies). Studies with mixed samples or without a DSM-IV-TR diagnosis were excluded.

Results

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Results of the retrieved publications are presented in five main sections. The first one describes the current hypotheses about the cause of immune abnormalities in major psychoses. In the second, neurodevelopment and progress theories are discussed. The third deals with immunological factors that could be thought of as possible candidates of markers of illness. The fourth describes the contribution of immunity to a dimensional diagnostic approach and the fifth describes studies comparing immuno-inflammatory features in schizophrenia and BD.

Hypotheses about immunological alterations in major psychoses

Introduction

Historically two arms of research have studied the possible relation between immunological abnormalities and major psychoses. The first was focused on the role of infectious agents (‘infective hypothesis’), while the other took into consideration the dysregulation of immuno-inflammatory mechanisms (‘inflammatory hypothesis’).

Infective hypothesis

Schizophrenia has been historically associated with cytomegalo and herpes' viral infections that would compromise the development of the CNS.[24] In addition, the serum levels of toxoplasma antibodies were found to be higher in schizophrenic patients than in the general population.[25] Toxoplasma could have a role in the cause of schizophrenia, as this parasite increases the CNS levels of kynurenic acid, an antagonist of glutamatergic N-methyl-D-aspartate receptor (NMDA) receptors.[26] Finally, a flu infection during pregnancy increases the risk of future development of schizophrenia probably due to a dysregulation of GABAergic transmission.[27]

With regard to BD, there are more scanty evidences about an association of infections and onset of symptoms; however, the infections of similar pathogens have been associated with both schizophrenia and BD. For example, with the exception of one paper,[28] the seroprevalence of Toxoplasma gondii infection was found to be higher in individuals with BD with respect to unaffected controls.[29-31] In addition the exposure to influenza epidemics was found to increase the risk for adult BD.[32] Finally, Pavuluri and Smith[33] reported the case of a patient affected by mononucleosis that subsequently developed BD and showed remission of symptoms and normalization of neuroimmune dysfunction after treatment with lithium.

Inflammatory hypothesis

The ‘inflammation’ hypothesis of schizophrenia was firstly formulated after the observation of the positive effects of anti-inflammatory treatment and of lower rates of rheumatoid arthritis in patients suffering from schizophrenia compared to the general population.[34]

Similarly, autoimmune thyroiditis was found to be frequently associated with BD,[35] as well as a good response to the anti-inflammatory agent minocycline.[36]

Praecox ‘stressors’, such as partum complications, are thought to be associated with overexpression of specific polymorphisms (e.g. inflammatory cytokines) that would be responsible for immune dysregulation associated with schizophrenia and BD.[37]

Role of the immune system in the pathophysiology of schizophrenia and BD

Introduction

Biological changes of schizophrenia, including immunological abnormalities, were traditionally explained by these two views:

  • A neurodevelopmental hypothesis suggests that a disruption of brain development during early life is responsible for later emergence of symptoms during adulthood
  • A progressive hypothesis suggests that symptoms and related neurotransmitter dysregulation is responsible for immunological changes that can be observed during the course of illness.[38]

BD was traditionally thought of as an early onset disorder that is clinically and biologically stable during the course of illness with the exception of acute relapses. The finding of a different biological profile in recent-onset versus chronic euthymic bipolars has changed this traditional vision in recent years in favor of the role of illness in determining biological changes, including immunological dysfunction.[39, 40] In addition, similarly to schizophrenia, the role of praecox stressors has been postulated in explaining prefrontal–subcortical dysfunction observed in BD.[41]

Contribution of immune system research to the neurodevelopmental model

The neurodevelopmental model of schizophrenia/BD states that immune alterations due to several factors, including decreased vitamin D, hypoferremia and zinc deficiency, are responsible for brain development abnormalities.23 Cytokines would be the mediators between immune abnormalities and CNS development.[6] In fact, cytokines may play an important role during neurodevelopment at all stages from the differentiation of ectoderm into neuroepithelium, to the renewal of neuroepithelial cells, which act as precursors for all neurons, microglia and adult progenitors as well as a framework for radial neuron migration. During neurogenesis, there is an overproduction of neurons and glia and cytokines act crucially to promote survival of cells, which are properly connected in the neural network, as well as to induce apoptosis of cells with impaired connections.[42]

In other words, cytokines represent a link between altered immune system, neurotransmission dysfunction and impaired neurodevelopment, all of which contribute to the onset of schizophrenia/BD in childhood or later life. In recent years, several studies have focused on infection and subsequent activation of inflammatory pathways during neurodevelopment.[43-45]

Two major hypotheses have been postulated: one argues that individual infections increase the risk of developing schizophrenia/BD; the second suggests that different infections act through common pathways, which may alter fetal brain development and increase risk of the disorder. On the basis of clinical and preclinical findings, cytokines have been proposed as key mediators of this common mechanism.[43, 45, 46]

As mentioned above, an increase of cytokines following a maternal infection may alter the immune status of the fetal brain, causing abnormal cellular development with subsequent brain damage.[44, 45] It has been well described that maternal immune activation induces increase of cytokines in the placenta (IL-1β, IL-6, TNF-α) and amniotic fluid (IL-6, TNF- α).[47, 48] Cytokines could act on the placenta, altering transfer of nutrients, oxygen, growth factors and maternal antibodies, all of which have a crucial effect on fetal development.[49]

However, it is not clear whether cytokines are altered in the fetal brain, even though animal models suggest that there could be a significant increase in IL-1β, IL-6, and INF-γ.[49, 50] Cytokines seem to act directly on developing neurons and cause a disruption on maturation of oligodendroglia as well as white matter abnormalities. In addition they could activate different potential mechanisms, such as stimulation of astroglia and microglia, to produce cytokines potentiating excitatory amino acids and nitric oxide, which lead to disrupted maturation of oligodendrocytes.[45, 51, 52]

Specifically, overall increase of maternal cytokines, including IL-8 and TNF-α, is correlated with several infections. Of note, IL-8 appears to be a key factor for neutrophil attraction as well as for release of lysosomal enzymes from neutrophils, leading to discharge of oxygen free radicals. TNF-α has been associated with chorioamnionitis[45, 53] and fetal infections.[45, 54]

Along with maternal infections, other factors have been considered to be involved in maternal immune activation alteration. For instance, nutritional deficits and stress have been linked with increase of inflammatory cytokines. In fact, chronic and acute stress has been associated with increased production of proinflammatory cytokines[55, 56] and decreased levels of anti-inflammatory ones.[57-59] On the other hand, life in an urban area and birth in winter–spring can enhance the risk of maternal infections with subsequent inflammatory response.[48, 60-62] However, it has not been clarified if cytokine fetal imbalance is able to induce itself an immune dysregulation in the adult brain.[42]

Contribution of immune system research to the progressive model

As an alternative to the ‘neurodevelopmental’ hypothesis of schizophrenia/BD, the ‘neurodegenerative’ hypothesis states that immunological alterations are secondary to the onset of illness and they can be observed during the progression of illness. It has been hypothesized that immunological alterations of schizophrenia and BD may be an adaptive response to microglial activation in mature CNS.[63] Of note, IL-6 seems to play a crucial role in both the disorders in determining biological changes observed during the course of illness.[7] IL-6 potentiates B lymphocyte proliferation: the hyperactivation of humoral immunity stimulates the tryptophan 2,3-dioxygenase enzyme with an increase of the transformation of the amino acid tryptophan in kynurenic acid[64] that acts as an NMDA antagonist.[65, 66] Another metabolite of tryptophan catabolism is 3-hydroxykynurenine, which is considered an endogenous oxidative stress generator, probably involved in cognitive symptoms.[67, 68] In support of this hypothesis, some studies show that a long duration of illness in schizophrenia/BD is associated with higher serum levels of IL-6.[69-71]

Immunological factors as biological markers of illness

Introduction

Immune dysregulation appears to play some role in the pathophysiology and outcome of major psychoses along with genetic factors and neurodevelopmental disturbances.[51, 72-74] For this reason, in recent years, researchers have tried to identify neuroimmunological markers, defined as any genetically or environmentally biological parameter, with the aim to identify individuals at risk and monitor the progression of illness.[75]

Immunological markers of schizophrenia
Cytokines

As mentioned above, a number of studies indicate the presence of immuno-inflammatory abnormalities in schizophrenia.[73, 76-81]

In recent years, several different models have been proposed for explaining the cytokine dysregulation observed in schizophrenia.[82] These models have been later used to explain also immunological abnormalities in BD.

The ‘macrophage T-lymphocyte hypothesis’ argues that chronically activated macrophages produce cytokines, such as IL-1, IL-2, TNF, IFN-α and IFN-γ, which could be the key mediators for schizophrenia.[83, 84] The illness would be, therefore, the result of a hyper-activation of cell-mediated immunity. In line with this hypothesis, some authors found higher levels of Th-1 cytokines in schizophrenic patients with respect to controls.[85]

The ‘Th-2 hypothesis’ postulates that in schizophrenia, there is a predominance of Th-2 lymphocytes.[22, 47, 72] In contrast with the previous hypothesis, the illness would be the result of a hyperactivation of humoral immunity. This is actually the most corroborated hypothesis in light of:

  1. Decreased in vitro production of IL-2 and IFN-γ pointing to a blunted production of Th1 cytokines;[86]
  2. decreased levels of neopterin, a product of activated macrophages;[87]
  3. increased production of IgE;[47] and
  4. increased CSF IL-4 levels: the key cytokine for the Th2 immune response.[88]

It can be hypothesized that patients with different symptoms show a predominance of humoral or cell-mediated immunity. In this sense, IL-6 can be thought of as the unifier cytokine, being increased by activated monocytes and Th2 immune response.

More recently, a variant of the macrophage T-lymphocyte hypothesis known as the ‘microglial hypothesis’ has been formulated, which suggests that proinflammatory cytokines and free radicals are released by activated CNS microglia, thus causing neural degradation, abnormal neurogenesis and white matter abnormalities, which could contribute to the pathogenesis of the disorder.[48]

Finally, a recent meta-analysis showed that cytokine alterations may vary with clinical status of schizophrenic patients, as in other inflammatory non-psychotic diseases, such as systemic lupus erythematosus and celiac disease.[89] Some cytokines (namely, IL-1β, IL-6, and TGF-β) might be state markers for acute relapse, while some others (IL-12, IFN-γ, TNF-α and sIL2R) could represent trait markers of schizophrenia.[89]

Chemokines

Chemokines act as chemoattractants to guide the migration of leukocytes. Most of the studies show that monocyte chemoattractant protein (MCP)-1 chemokine serum levels are increased in schizophrenic patients.[90, 91] Some authors hypothesize a role of this chemokine in the development of metabolic syndrome.[92] Of note, in schizophrenics, there is frequently a polymorphism of the gene of the chemokine MCP-1, which seems responsible for resistance to antipsychotics and could be present in patients with more severe subtypes.[73] In addition, one study found higher serum levels of chemokine CCL11 in schizophrenic patients with respect to healthy controls: this finding would reinforce the view that schizophrenic disorder may be associated with a Th1/Th2 imbalance with a shift toward a Th2 immune response, being CCL11 ligand preferentially expressed in Th2 lymphocytes.[93]

Immune cells counting

The results are inconsistent as the majority of studies measured the effects of antipsychotics and not lymphocyte distribution in drug-naïve patients. However, study results are generally concordant in showing reduced T cells and increased B cells in drug-naïve patients and an inverse pattern when patients are medicated.[94]

Polyunsaturated fatty acids

A number of data showed decreased concentrations of polyunsaturated fatty acids (PUFA) in both brain and peripheral membranes of schizophrenics.[95] It has been hypothesized that this decrease can be due to the increased degradation of arachidonic acid as a result of altered immune function and overproduction of prostaglandins, particularly prostaglandin E.[96] In line with this view, recent studies showed that adjuvant aspirin and celecoxib reduce symptoms of schizophrenia spectrum disorders.[97-99] The rationale for using cyclooxygenase antagonists in the treatment of major psychoses is, in fact, the upregulation of arachidonic acid metabolism associated with inflammation and excess proinflammatory cytokines.[99, 100] Actually, a very recent study found an overexpression of genes related to the arachidonic acid signaling pathway in schizophrenic patients compared to healthy controls.[101]

Antioxidant defense system

In recent years, some authors have speculated that an impairment of the antioxidant defense system (AODS) could be responsible for neuron damage in schizophrenic patients.[102] AODS, in fact, prevents cellular damage of free radicals that are overproduced during inflammatory processes. AODS includes enzymatic antioxidants (superoxide dismutase, catalase and glutathione peroxidase) and non-enzymatic ones (albumin, bilirubin, uric acid, ascorbic acid, tocopherol, glutathione).[102] Schizophrenic patients are expected to have cellular/plasma decreased levels of antioxidants. With regard to non-enzymatic antioxidants, albumin,[103] bilirubin,[104] uric acid,[105] ascorbic acid,[106] glutathione[107] and tocopherol[108] were all found to be decreased in schizophrenics' plasma. Contrasting results were found regarding superoxide-dismutase serum/cellular concentrations: it has been speculated that this enzyme might be raised in chronic patients as a compensatory response to oxidative stress.[102] Nitric oxide, which plays an important regulatory/modulatory role in a variety of inflammatory conditions, is a source of free radicals and is supposed to be increased in schizophrenic patients. However, the inconsistent findings[109, 110] exclude NO as a diagnostic marker to distinguish schizophrenics from healthy controls.

Hormonal regulation

One of the effects of immune dysregulation of schizophrenics is the HPA dysfunction indicated by high cortisol and adrenocorticotropic hormone (ACTH).[111] In addition, prolactin serum levels were found to be increased in drug-naïve schizophrenic patients in comparison with controls, but the correlation with symptoms severity and outcome is uncertain.[112] Hyperinsulinemia has been found in schizophrenic patients and it has been associated with abnormal inflammation responses.[113] Finally, high plasma levels of T3 and T4 were found in schizophrenics and thyroid hormogenesis was thought to be enhanced by higher peroxides plasma levels in schizophrenics compared to healthy controls.[114]

Immunological markers of BD
Cytokines

The central role of cytokines in mood disorders is predominately supported by studies in unipolar depression. The macrophage hypothesis was sustained after the recognition of induction of a depressive syndrome in up to 50% of healthy volunteers by INF-α administration and of a high comorbidity between depression and inflammatory illnesses.[115] More recently, there has been increasing evidence suggesting that chronic, mild inflammatory processes both in the periphery and the brain are involved in the pathophysiology of BD.[71] Some complement factors (C3, C4 and C6) and C-reactive protein (CRP) levels have been found to be higher in BD than controls[116] and acute phase protein response has been shown not only in major depression, but also in schizophrenia and mania,[117] suggesting that all these conditions may result in an activation of inflammatory response. Significantly increased levels of cytokines, such as IL-1 and its receptors, have been found in the post-mortem frontal cortex of bipolar patients, compared to healthy controls.[118]

Some studies demonstrated altered production of proinflammatory cytokines in bipolar patients compared to healthy controls, with differences in cytokine serum levels between different mood episodes. A key feature of BD is shifts in mood states, and it has been suggested that immune system activation may vary across mood episodes of different polarity.[119] During depressive episodes, an increase in proinflammatory cytokines, such as IL-8, CRP and TNF-α, was significant among patients with BD versus controls;[20, 119, 120] whereas in mania, levels of IL-6, IL-8 and TNF-α were found to be increased, with inconsistent results for IL-4.[9, 20, 121] In another study, cytokine levels were compared in depressed, manic and euthymic patients with BD, finding an increase in IL-2, IL-4 and IL-6 levels in mania and only increase of IL-6 during depression, whereas euthymic patients showed an increase of IL-4.[121] These data would suggest that changes in proinflammatory cytokines could be related to mood state, as some differences were more pronounced during acute episodes than euthymia. This hypothesis is consistent with another report showing that elevation of IL-6 in manic patients resolves with clinical remission after treatment with mood stabilizers, while TNF-α levels do not appear to change.[7] Therefore, some components of inflammatory cascade could be state markers, but others, such as TNF-α, could be trait markers of BD. However, other results do not support these findings and the discrepancy could be explained by use of smaller sample size, their heterogeneity regarding mood symptoms, length of illness and effect of medications.[116, 119, 120]

There are also data suggesting that BD is associated with cytokine genetic polymorphisms.[122-125] Interestingly, a study found that IL-6 alleles had different distribution between adults with BD and controls, and in offspring (with and without mood disorder) versus controls as well as in offspring with versus without mood disorders.[124] Contradictory findings were reported for TNF-α polymorphism: two studies described an association between TNF-α2 allele and BD,[122, 123] whereas some others studies were negative.[126, 127]

In summary, aberrant expression of inflammatory genes may be considered a biological marker or an endophenotype for BD,[116] consistent with the above findings about state and trait markers of the disorder. In contrast to this consideration, a recent study with twins affected by BD demonstrated that proinflammatory gene expression observed in bipolar patients is mostly explained by environmental factors, although in a small sub-cluster of genes, genetic influences could dominate.[128]

In general, hypotheses on the mechanisms by which alterations in inflammatory pathways could induce episodes and symptoms in BD are lacking or doubtful. Recent studies, given the established link between muscarinic M2 receptor and cognition,[129] focused their attention on reduction of muscarinic M2 receptors levels in peripheral tissue inflammation. They highlighted the role of TNF-α in reducing the expression of this receptor and suggested that increased levels of TNF-α (as shown in depressive disorder) could be implicated in decreased levels of M2 receptors in BD and depression. According to this hypothesis, the link between M2 receptor, inflammation and cognition could provide a mechanism by which changes in inflammatory pathways could be one of the causes of cognitive deficits associated with BD.[130] This is consistent with the fact that cognitive impairment is one of the core features of the disorder and at least some of it is related to lifetime number of episodes.[131]

An alternative pathogenetic hypothesis states, similarly to schizophrenia, that bipolar mania is the result of an increase of tryptophan breakdown pathway. This would be consistent with the observation of an increase of IL-6 serum levels during manic episodes, associated with the activation of tryptophan 2,3-dioxygenase.[132] Kynurenine pathway overactivation can be due also to lower serum levels of the immunosuppressive TGF-β1 observed in manic patients compared to healthy controls.[133]

Chemokines

In manic patients, one study found increased serum levels of CCL11 similarly to schizophrenics,[134] while in euthymic bipolars, no differences were observed with respect to controls.[135] In addition, a study on a polymorphism of the chemokine MCP-1 (a cytokine playing a key role in innate immunity, named alternatively CCL2) showed a significantly higher frequency of the allele A in BD compared to unipolar depression, with a more frequent number of lifetime suicide attempts independent of diagnosis.[125] Finally, increased serum levels of CCL2 in BD were found supporting the hypothesis of a Th1 hyperactivation.[136]

Immune cells counting

In BD, a monocyte proinflammatory state and cell-mediate immunity activation has been reported as a result of indirect evidences like the plasma increases of monocyte-related cytokines.[136] However, a study reported leukocytosis and increased monocytes in bipolar patients.[137]

PUFA

Preliminary data would indicate a disturbance in brain lipid concentrations of bipolar patients with the majority of results derived form post-mortem studies.[138] In a post-mortem study, arachidonic acid concentrations in orbitofrontal cortex were found to be decreased compared to healthy controls.[139] Interestingly, a recent paper reported elevations in cyclooxygenase and membrane prostaglandin E synthase in the BD cortex, which indicate a hyperactivation of arachidonic acid cascade in bipolars.[140]

AODS

Preliminary data would indicate oxidative imbalance in BD as well as in schizophrenia.[141] Total oxidant status would be high in the first stages of illness, while in chronic patients, increased AODS was found.[141] In support of this speculation, a paper reported increased levels of the anti-oxidant enzyme glutathione S-transferase in the late stage of illness.[142]

Hormonal regulation

In depression, cytokines seem to activate the HPA axis, to increase CRH in both hypothalamus and amygdala, and to affect the monoaminergic system.[143] In contrast, during manic phases, an inverse hormonal pattern would be observed with a decrease of plasma cortisol levels.[144, 145]

Clinical dimensions and immunological patterns

Introduction

Some authors propose to substitute the categorical approach to psychiatric nosography in favor of a dimensional one in light of overlapping symptoms and biological features between diagnoses.[146] In this section the contribution of immunology to the dimensional approach in schizophrenia and BD is summarized.

Dimensionality and schizophrenia

Positive symptoms have been hypothesized to be the result of changes in the enzymatic activity of tyrosine hydroxylase, which is supposed to be enhanced by proinflammatory activity.[147] In addition, increased autoimmunity was found in patients with positive symptoms: a study showed that the progression of positive symptoms was coupled with gradual increase of autoantibodies to nerve growth factor.[148]

Indoleamine-pyrrole 2,3-dioxygenase activation secondary to proinflammatory state would be involved in the pathogenesis of negative symptoms of schizophrenia by two mechanisms: the depletion of serotonin[149] and the production of kynurenic acid.[150] In support of this view, several studies report an association between peripheral or central inflammation and severity of negative symptoms.[150] Of note, concentrations of plasma IL-6 and IL-8[151] were reported to positively correlated with the severity of negative symptoms. Furthermore, increased CRP levels were found in patients with predominant negative symptoms.[152]

Similarly, cognitive schizophrenia symptoms would be the result of the effects of kynurenic acid on NMDA receptor complex as well as on cholinergic neurotransmission (blockade of nicotinic acetylcholine receptors, especially α7 types).[153] In support of the correlation between inflammation and cognitive symptoms, a study found an association between CRP and severity of cognitive symptoms.[154]

Finally, a study found an association between microglial density and suicide in schizophrenic patients, but these results have not been replicated.[155]

Dimensionality and BD

Studies associating immunity and clinical dimension in BD are preliminary; as are those about HPA axis dysregulation. Higher cortisol plasma levels were found in dysphoric bipolars than in euphoric ones.[145] In addition, haplotype variation at the CRHR2 locus was associated with suicidal behaviour.[156]

Studies comparing abnormalities in schizophrenia and BD

In general, few studies have investigated similarities and differences in immuno-inflammatory dysregulation between BD and schizophrenia. From one side, genetic studies have shown an association of polymorphism in cytokines with both schizophrenia and mood disorders.

A significant excess of a polymorphism in the promoter region of the IL-1B gene was found among subjects with BD and schizophrenia compared to controls, especially in those who had a family history of these disorders. In other words, IL-1 cluster genetic variability could represent a common genetic susceptibility for BD and schizophrenia.[157]

On the other side, there are conflicting results concerning the association between polymorphisms of TNF-α and both schizophrenia and BD. In some studies, a specific TNF-α polymorphism was present in both schizophrenic and bipolar patients;[158] but in another study, this was only present in schizophrenic patients, and not in controls or BD patients.[127]

Plasma levels of inflammatory markers in BD and schizophrenic patients versus healthy controls have been investigated. The patients, independently from the diagnosis, shared the same inflammatory profile and they had highly statistically significantly elevated levels of two inflammatory markers, named sTNF-R1 (a stable and reliable marker of the activity of TNF-α system) and von Wildebrand factor (vWf), which is an endothelial-related inflammatory marker.[7, 135] The combination of elevation of TNF-α and vWf would also indicate the presence of endothelial-related inflammation in both disorders.[159]

The comparison of cytokine levels in bipolar euthymic and schizophrenic patients versus healthy controls showed an increase in IL-6 in schizophrenia compared to BD and healthy controls, and in the same study, IL-10 was increased in both schizophrenic and bipolar patients versus controls.[5] On the other side, manic patients showed an immunological profile similar to schizophrenic patients versus controls, where IL-6 was more specific for schizophrenia and IL-6 and IL-2R for mania (Table 1).[160]

Table 1. Similarities and differences of BD versus schizophrenia with regard to immunology
  1. BD, bipolar disorder; IL, interleukin; MCP-1, monocyte chemoattractant protein; PUFA, polyunsaturated fatty acids.

Infectious hypothesis

Shared features: Association with Toxoplasma gondii infection and flu epidemics[25-32]

Etiopathogenetic model

Shared features: A role of praecox stressors (neurodevelopment model) and further biological changes after onset (neuroprogression)[38-41]

Cytokines

Shared features:

Differences: Increased IL-6 can be the result of monocyte activation (BD)[115, 136] or Th2 activation (schizophrenia)[22, 47, 72]

Chemokines

Shared features:

  •  
    Increased CCL11 in manic patients and schizophrenia[93, 134]
  •  
    Increased levels of MCP-1 alternatively named CCL2[90, 91, 136]

Immune cells counting

Differences: Increased B cells and decreased T cells for schizophrenia, while increased monocytes for BD[94, 137]

PUFA

Shared features: Decreased PUFA in brain membranes as a result of arachidonic acid cascade hyperactivation[95, 96, 101, 138-140]

Antioxidant defense system

Shared features: Increased oxidant status in first years of illness and potentiated antioxidant system in chronic patients[102-108, 141, 142]

Hormonal regulation

Shared features: High cortisol levels in schizophrenia and bipolar depression[111, 143]

Differences: Decreased plasma cortisol levels in mania[144, 145]

Genetics

Shared features: Polymorphism in the promoter region of IL-1B[157]

The role of medications has to be taken into account when comparing immunological abnormalities between schizophrenia and BD. It is actually debated if the different abnormalities observed in the two disorders are the result of a distinct pathogenesis or of the effects of medications, such as lithium or clozapine.[161]

Discussion

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Immunological abnormalities are present in major psychoses with more evidences regarding schizophrenia. The similarities (e.g. serum increase of IL-6 concentrations) between schizophrenia and BD support a ‘continuum’ between the two disorders. In particular, cytokine dysregulation could be responsible for the neurodegenerative aspects observed both in schizophrenia and in BD, particularly in patients with long duration of illness.[1] On the other hand, schizophrenic illness would appear to be more related to a Th2 immune overactivation, while bipolar patients would show more frequently a monocyte-related immune response. It can be speculated that the different symptoms of schizophrenia versus BD would be the result of a distinct immunological profile with a shared genetic predisposition. This model explains the different course of first-episode psychotic patients. In some of these patients, a prevalent Th2 immune response will be associated with negative/cognitive symptoms and a diagnosis of schizophrenia, while a monocyte-related response with affective symptoms will be associated with a diagnosis of BD. This hypothesis is concordant with the current view that intermediate phenotypes between schizophrenia and BD are existing and there is not a clear distinction between the two disorders in terms of biological markers (Fig. 1).

figure

Figure 1. Interleukin-6: A common biological marker of schizophrenia and bipolar disorder? BD, bipolar disorder; HPA, hypothalamic–pituitary axis; IDO, indoleamine-pyrrole 2,3-dioxygenase; IFN, interferon; NMDA, N-methyl-D-aspartate receptor; PGE, prostaglandin E.

Download figure to PowerPoint

Moreover, schizophrenia and BD frequently share the same pharmacological treatment with atypical antipsychotics and there are some available data concerning the effects of these drugs on patients' immunity and their effect, specifically on the immuno-inflammatory system.[162] In this light, preliminary findings indicate that atypical antipsychotics may reverse immuno-inflammatory abnormalities at the same time with the improvement of clinical symptoms.[85, 163, 164] Interestingly, a recent paper showed that quetiapine treatment was associated with a parallel improvement of positive symptoms and a normalization of IL-2 receptor serum concentrations.[165]

All these data open the way to new treatment options, including anti-inflammatory medications. Accordingly, a recent study on augmentative treatment with minocycline to antipsychotics found this combination to be effective in treating negative symptoms in early schizophrenia.[166] Similarly, low doses of aspirin resulted in reduced risk of clinical deterioration in BD patients treated with lithium.[167] Taken as a whole, these data indicate that the use of anti-inflammatory agents in the treatment of schizophrenia and BD are promising, but further research is needed to assess to which extent anti-inflammatory agents improve symptoms, particularly cognitive impairment, which is associated with neurodegenerative features in major psychoses.

Some limitations of the present paper have to be briefly described. A number of important conditions (e.g. age, lifestyle, obesity, smoking) influence the levels of circulating cytokines in psychiatric patients. These factors might have influenced the results of the cited studies.[84] In addition, there is increasing evidence of immunological abnormalities in major psychoses, but the importance of these findings is still debated. This paper tried to give a comprehensive vision of the topic as much as possible, but only future research will be able to indicate the importance of these data in terms of diagnosis and pharmacological management of psychiatric disorders.

Acknowledgments

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References

Professor Altamura is a Merck and Astra Zeneca consultant, and a member of the speaker's bureaus for Sanofi, Lilly and Pfizer. Dr Buoli is a Roche consultant. Dr Pozzoli does not have any affiliation with or financial interest in any organization that might pose a conflict of interest with the present article.

References

  1. Top of page
  2. Abstract
  3. Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. References
  • 1
    Altamura AC, Buoli M, Serati M. Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry. 2011; 1: 8190.
  • 2
    Kunz M, Ceresér KM, Goi PD et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: Differences in pro- and anti-inflammatory balance. Rev. Bras. Psiquiatr. 2011; 33: 268274.
  • 3
    Murray RM, Sham P, Van Os J, Zanelli G, Cannon M, McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr. Res. 2004; 71: 405416.
  • 4
    Niculescu AB, Lulow LL, Odgen CA et al. PhenoChipping of psychotic disorders: A novel approach for deconstructing and quantitating psychiatric phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006; 141: 653662.
  • 5
    Craddock N, Owen MJ. Rethinking psychosis: The disadvantages of a dichotomous classification now outweigh the advantages. World psychiatry. 2007; 6: 8491.
  • 6
    Altamura AC, Pozzoli S, Fiorentini A, Dell'Osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog. Neuropsychopharmacol Biol. Psychiatry 2013; 42: 6370.
  • 7
    Weizman R, Bessler H. Cytokines: Stress and immunity: An overview. In: Plotnikoff NP , Faith RE , Murgo AJ , Good RA (eds). Cytokines, Stress and Immunity. CRC Press, Boca Raton, 1998; 115.
  • 8
    Kronfol Z, Remick DG. Cytokines and the brain: Implications for clinical psychiatry. Am. J. Psychiatry 2000; 157: 683694.
  • 9
    Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007; 104: 9195.
  • 10
    Maier SF, Watkin LR. Cytokines for psychologists: Implication of bidirectional immune-to-brain communication for understanding behaviour, mood and cognition. Psychol. Rev. 1998; 105: 83107.
  • 11
    Schaefer M, Schmidt F, Neumer R, Scholler G, Schwarz M. Interferon-alpha, cytokines and possible implications for mood disorders. Bipolar Disord. 2002; 4: 111113.
  • 12
    Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240: 321324.
  • 13
    Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 1993; 337: 543567.
  • 14
    McGeer PL, McGeer EG. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. 1995; 21: 195218.
  • 15
    Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol Biol. Psychiatry 2005; 29: 201217.
  • 16
    Aloisi F, Borsellino G, Caré A et al. Cytokine regulation of astrocyte function: In-vitro studies using cells from the human brain. Int. J. Dev. Neurosci. 1995; 13: 265274.
  • 17
    Muñoz-Fernández MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 1998; 56: 307340.
  • 18
    Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behav. Immun. 2002; 16: 513524.
  • 19
    Schimtz T, Chew LJ. Cytokines and myelination in the central nervous system. Scientific World Journal 2009; 8: 11191147.
  • 20
    O'Brien SM, Scully P, Scott L, Dinan TG. Cytokines profiles in bipolar affective disorder: Focus on acutely ill patients. J. Affect. Disord. 2006; 90: 263267.
  • 21
    Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharm. 2008; 28: 15151520.
  • 22
    Potvin S, Stip E, Sephery AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokines alterations in schizophrenia: A systematic quantitative review. Biol. Psychiatry 2008; 63: 801808.
  • 23
    Anderson G, Berk M, Dodd S et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2013; 42: 14.
  • 24
    Krause D, Matz J, Weidinger E et al. The association of infectious agents and schizophrenia. World J. Biol. Psychiatry 2010; 11: 739743.
  • 25
    Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr. Bull. 2007; 33: 729736.
  • 26
    Schwarcz R, Hunter CA. Toxoplasma gondii and schizophrenia: Linkage through astrocyte-derived kynurenic acid? Schizophr. Bull. 2007; 33: 652653.
  • 27
    Nyffeler M, Meyer U, Yee BK. Maternal immune activation during pregnancy increases limbic GABA A receptor immunoreactivity in the adult offspring: Implications for schizophrenia. Neuroscience 2007; 143: 5162.
  • 28
    Mortensen PB, Pedersen CB, McGrath JJ et al. Neonatal antibodies to infectious agents and risk of bipolar disorder: A population-based case-control study. Bipolar Disord. 2011; 13: 624629.
  • 29
    Tedla Y, Shibre T, Ali O et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case-control study. Ethiop . Med. J. 2011; 49: 211220.
  • 30
    Hamdani N, Daban-Huard C, Lajnef M et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J. Affect. Disord. 2013; 148: 444448.
  • 31
    Pearce BD, Kruszon-Moran D, Jones JL. The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol. Psychiatry 2012; 72: 290295.
  • 32
    Machón RA, Mednick SA, Huttunen MO. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 1997; 54: 322328.
  • 33
    Pavuluri MN, Smith M. A neuroimmune hypothesis for the aetiopathology of viral illness and manic depression: A case report of an adolescent. J. Affect. Disord. 1996; 39: 711.
  • 34
    Gorwood P, Pouchot J, Vinceneux P et al. Club Rhumatisme et Inflammation. Rheumatoid arthritis and schizophrenia: A negative association at a dimensional level. Schizophr. Res. 2004; 66: 2129.
  • 35
    Vonk R, van der Schot AC, Kahn RS et al. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol. Psychiatry 2007; 62: 135140.
  • 36
    Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: Therapeutic potential in psychiatry. CNS Drugs. 2012; 26: 391401.
  • 37
    Di Nicola M, Cattaneo A, Hepgul N et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013; 31: 9095.
  • 38
    McGrath JJ, Féron FP, Burne TH, Mackay-Sim A, Eyles DW. The neurodevelopmental hypothesis of schizophrenia: A review of recent developments. Ann. Med. 2003; 35: 8693.
  • 39
    Lake CR, Hurwitz N. Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease–there is no schizoaffective disorder. Curr. Opin. Psychiatry 2007; 20: 365379.
  • 40
    Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM. Neuroprogression in bipolar disorder. Bipolar Disord. 2012; 14: 356374.
  • 41
    Roybal DJ, Singh MK, Cosgrove VE et al. Biological evidence for a neurodevelopmental model of pediatric bipolar disorder. Isr. J. Psychiatry Relat. Sci. 2012; 49: 2843.
  • 42
    Deverman BE, Patterson P. Cytokines and CNS development. Neuron 2009; 64: 6177.
  • 43
    Gilmore JH, Jarskog LF. Exposure to infection and brain development: Cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 1997; 24: 365367.
  • 44
    Dammann O, Leviton A. Maternal intrauterine infection, cytokines and brain damage in the preterm newborn. Ped. Res. 1997; 42: 18.
  • 45
    Brown AS, Derkits EJ. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am. J. Psychiatry 2010; 167: 261280.
  • 46
    Jonakait GM. The effects of maternal inflammation on neuronal development: Possible mechanisms. Int. J. Dev. Neurosci. 2007; 25: 415425.
  • 47
    Schwarz MJ, Muller N, Riedel M Ackenheil M. The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001; 56: 483486.
  • 48
    Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009; 63: 257265.
  • 49
    Patterson PH. Immune involvement in schizophrenia and autism. Etiology, pathology and animal models. Behavioural Brain Research. 2009; 204: 313321.
  • 50
    Elovitz MA, Mrinalini C, Sammel MD. Elucidating the early signal transduction pathways leading to fetal brain injury in preterm birth. Pediatr. Res. 2006; 59: 5055.
  • 51
    Altamura AC, Boin F, Maes M. HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotics treatment. Eur. Neuropsychopharmacol. 1999; 10: 14.
  • 52
    Davis KL, Stewart DG, Friedman JI et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003; 60: 443456.
  • 53
    Saji F, Samejima Y, Kamiura S, Sawai K, Shimoya K, Kimura T. Cytokine production in chorioamnionitis. J. Reprod. Immunol. 2000; 47: 185196.
  • 54
    Baud O, Emilie D, Pelletier E et al. Amniotic fluid concentrations of interleukin-1beta, interleukin-6, and TNF-alpha in chorioamnionitis before 32 weeks of gestation: Histological association and neonatal outcome. Br. J. Obstet. Gynaecol. 2000; 106: 7277.
  • 55
    Leonard BE, Song C. Stress, depression, and the role of cytokines. Adv. Exp. Med. Biol. 1999; 461: 251265.
  • 56
    Watkins LR, Nguyen KT, Lee JE, Maier SF. Dynamic regulation of proinflammatory cytokines. Adv. Exp. Med. Biol. 1999; 461: 153178.
  • 57
    Maes M, Song C, Lin A et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313318.
  • 58
    Goebel MU, Mills PJ, Irwin MR, Ziegler MG. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: Differential effects and pathways. Psychosom. Med. 2000; 62: 591598.
  • 59
    Deinzer R, Granrath N, Stuhl H et al. Acute stress effects on local Il-1beta responses to pathogens in a human in vivo model. Brain Behav. Immun. 2004; 18: 458467.
  • 60
    Coe CL, Lubach GR. Prenatal origins of individual variation in behaviour and immunity. Neurosci. Behav. Rev. 2005; 29: 3949.
  • 61
    Merlot E, Couret D, Otten W. Prenatal stress, fetal imprinting and immunity. Brain Behav. Immun. 2008; 22: 4251.
  • 62
    Shen Q, Li ZQ, Sun Y et al. The role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: Implications for schizophrenia. Schizophr. Res. 2008; 99: 4855.
  • 63
    Connor CM, Crawford BC, Akbarian S. White matter neuron alterations in schizophrenia and related disorders. Int. J. Dev. Neurosci. 2011; 29: 325334.
  • 64
    Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123129.
  • 65
    Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006; 10: 131148.
  • 66
    Müller N, Myint AM, Schwarz MJ. Kynurenine pathway in schizophrenia: Pathophysiological and therapeutic aspects. Curr. Pharm. Des. 2011; 17: 130136.
  • 67
    Yao JK, Dougherty GG Jr, Reddy RD et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 2010; 15: 938935.
  • 68
    Condray R, Dougherty GG Jr, Keshavan MS et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 2011; 14: 756767.
  • 69
    Ganguli R, Brar JS, Rabin BS. Immune abnormalities in schizophrenia. Evidence for the autoimmune hypothesis. Harv. Rev. Psychiatry 1994; 2: 7083.
  • 70
    Zhang XY, Zhou DF, Cao LY et al. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004; 65: 940947.
  • 71
    Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity and treatment of bipolar disorder: A systematic review of the literature. J. Clin. Psychiatry 2009; 70: 10781090.
  • 72
    Muller N, Riedel M, Ackenheil M, Schwarz MJ. The role of immune function in schizophrenia: An overview. Eur. Arch. Psychiatry Clin. Neurosci. 1999; 249: 6268.
  • 73
    Mundo E, Altamura AC, Vismara S et al. MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005; 132: 14.
  • 74
    Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. Eur. Arch. Psychiatry Clin. Neurosci. 2000; 250: 274285.
  • 75
    Stöber G, Ben-Shachar D, Cardon M et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J. Biol. Psychiatry 2009; 10: 127155.
  • 76
    van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 1998; 87: 129136.
  • 77
    Kaminska T, Wyoska A, Marmurowska-Michalowska H. Investigation of serum cytokines levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz.) 2001; 29: 439445.
  • 78
    Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and their biological relatives. Schizophr. Res. 2006; 84: 180182.
  • 79
    Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia: An overview. Eur. Arch. Psychiatry Clin. Neurosci. 1996; 20: 269273.
  • 80
    Naudin J, Capo C, Giusano B, Mège JL, Azorin JM. Elevated circulating levels of interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr. Res. 1997; 26: 227233.
  • 81
    Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr. Res. 1998; 32: 915.
  • 82
    Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin. Neurosci. 2010; 64: 217230.
  • 83
    Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med. Hypotheses 1995; 45: 135141.
  • 84
    Drexhage RC, Knijff EM, Padmos RC et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev. Neurother. 2010; 10: 5976.
  • 85
    Kim YK, Myint AM, Lee BH et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 11291134.
  • 86
    Müller N, Riedel M, Ackenheil MV et al. Cellular and humoral immune system in schizophrenia: A conceptual re-evaluation. World J. Biol. Psychiatry 2000; 1: 173179.
  • 87
    Schwarz MJ, Riedel M, Ackenheil M, Müller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 2000; 47: 2933.
  • 88
    Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol. 1997; 159: 29942999.
  • 89
    Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biol. Psychiatry 2011; 70: 663671.
  • 90
    Reale M, Patruno A, De Lutiis MA et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci. 2011; 12: 13.
  • 91
    Zakharyan R, Boyajyan A, Arakelyan A, Melkumova M, Mrazek F, Petrek M. Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. Cytokine 2012; 58: 351354.
  • 92
    Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012; 37: 19011911.
  • 93
    Teixeira AL, Reis HJ, Nicolato R et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2008; 32: 710714.
  • 94
    Steiner J, Jacobs R, Panteli B et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010; 260: 509518.
  • 95
    van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr. Res. 2012; 141: 153161.
  • 96
    Yao JK, van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int. Rev. Neurobiol. 2004; 59: 297326.
  • 97
    Akhondzadeh S, Tatabase M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2006; 84: 180118.
  • 98
    Laan W, Grobbee DE, Selte JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010; 71: 520527.
  • 99
    Muller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpiride treatment. Schizophr. Res. 2010; 121: 118124.
  • 100
    Sublette ME, Russ MJ, Smith GS. Evidence for a role of the arachidonic acid cascade in affective disorders: A review. Bipolar Disord. 2004; 6: 95105.
  • 101
    Tang B, Capitao C, Dean B, Thomas EA. Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res. 2012; 196: 201206.
  • 102
    Yao JK, Keshavan MS. Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid. Redox Signal. 2011; 15: 20112035.
  • 103
    Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, Lee CU. Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004; 50: 5456.
  • 104
    Vitek L, Lenicek M, Jirsa M et al. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. Psychiatry Res. 2010; 178: 449450.
  • 105
    Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998; 80: 2939.
  • 106
    Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrović B, Buzina R. Vitamin C status in schizophrenia. Biol. Psychiatry 1990; 28: 959966.
  • 107
    Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol Biol. Psychiatry 2009; 33: 11781183.
  • 108
    Brown K, Reid A, White T et al. Vitamin E, lipids, lipid peroxidation product and tardive dyskinesia. Biol. Psychiatry 1998; 43: 863867.
  • 109
    Minutolo G, Petralia A, Dipasquale S, Aguglia E. Nitric oxide in patients with schizophrenia: The relationship with the severity of illness and the antipsychotic treatment. Expert Opin. Pharmacother. 2012; 13: 19891997.
  • 110
    Zhang XY, Zhou DF, Shen YC et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012; 62: 19281934.
  • 111
    Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 10651070.
  • 112
    Shrivastava A, Johnston M, Bureau Y, Shah N. Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: Is it a predictive factor? Innov. Clin. Neurosci. 2012; 9: 1721.
  • 113
    Harris LW, Guest PC, Wayland MT et al. Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology 2013; 38: 752766.
  • 114
    Akiibinu MO, Ogundahunsi OA, Ogunyemi EO. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 2012; 5: 169.
  • 115
    Smiths RS. The macrophage theory of depression. Med. Hypotheses 1991; 35: 298306.
  • 116
    Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 2011; 45: 156161.
  • 117
    Maes M, Delange J, Ranjan R et al. Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res. 1997; 66: 111.
  • 118
    Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010; 15: 384392.
  • 119
    Ortiz-Dominguez A, Hernandez ME, Berlanga C et al. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord. 2007; 9: 596602.
  • 120
    Kupka RW, Breunis MN, Knijff E, Ruwhof C, Nolen WA, Drexhage HA. Immune activation, steroid resistancy and bipolar disorder. Bipolar Disord. 2002; 2: 7374.
  • 121
    Brietzke E, Sterz L, Fernandes BS et al. Comparison of cytokines levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009; 116: 214217.
  • 122
    Kim KW, Jun TY, Pae CU et al. Association study of tumor necrosis-alpha gene polymorphism in schizophrenia and bipolar disorder. J. Korean Neuropsychiatr. Association. 2003; 42: 559563.
  • 123
    Czerski PM, Rybakowski F, Kapelski P et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008; 57: 8894.
  • 124
    Padmos RC, Hillegers MHJ, Knijff EM et al. A discriminating messenger RNA signature for bipolar disorder formed an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008; 65: 395407.
  • 125
    Altamura AC, Mundo E, Cattaneo E et al. The MCP-1 gene (SCYA2) and mood disorders: Preliminary results of a case-control association study. Neuroimmunomodulation 2010; 17: 126131.
  • 126
    Middle F, Jones I, Robertson E, Lendon C, Craddock N. Tumor necrosis factor alpha and bipolar affective puerperal psychosis. Psychiatr. Genet. 2000; 10: 195198.
  • 127
    Meira-Lima IV, Pereira AC, Mota GF et al. Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: Further support for an association with schizophrenia. Mol. Psychiatry 2003; 8: 718720.
  • 128
    Padmos RC, Van Baal GC, Vonk R et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: A twin study. Arch. Gen. Psychiatry 2009; 66: 957965.
  • 129
    Jones KA, Porjesz B, Almasy L et al. Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: Implications for human brain dynamics and cognition. Int. J. Psychophysiol. 2004; 53: 7590.
  • 130
    Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Behav. Rev. 2011; 35: 804817.
  • 131
    Robinson LJ, Ferrier N. Evolution of cognitive impairment in bipolar disorder: A systematic review of cross-sectional evidence. Bipolar Disord. 2006; 8: 103116.
  • 132
    Myint AM, Kim YK, Verkerk R et al. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. 2007; 102: 6572.
  • 133
    Kim SJ, Lee HJ, Koo HG et al. Impact of IL-1 receptor antagonist gene polymorphism on schizophrenia and bipolar disorder. Psychiatr. Genet. 2004; 14: 165167.
  • 134
    Barbosa IG, Rocha NP, Bauer ME et al. Chemokines in bipolar disorder: Trait or state? Eur. Arch. Psychiatry Clin. Neurosci. 2013; 263: 159165.
  • 135
    Brietzke E, Kauer-Sant'Anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009; 23: 10791082.
  • 136
    Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011; 25: 12061213.
  • 137
    Cassidy F, Wilson WH, Carroll BJ. Leukocytosis and hypoalbuminemia in mixed bipolar states: Evidence for immune activation. Acta Psychiatr. Scand. 2002; 105: 6064.
  • 138
    Igarashi M, Ma K, Gao F et al. Brain lipid concentrations in bipolar disorder. J. Psychiatr. Res. 2010; 44: 177182.
  • 139
    McNamara RK, Jandacek R, Rider T et al. Deficits in docosahexanoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008; 160: 285299.
  • 140
    Kim HW, Rapoport SI, Rao J. Altered arachidonic acid cascade enzymes in post-mortem brain from bipolar disorder patients. Mol. Psychiatry 2011; 16: 419428.
  • 141
    Yumru M, Savas HA, Kalenderoglu A, Bulut M, Celik H, Erel O. Oxidative imbalance in bipolar disorder subtypes: A comparative study. Prog. Neuropsychopharmacol Biol. Psychiatry 2009; 33: 10701074.
  • 142
    Andreazza AC, Kapczinski F, Kauer-Sant'Anna M. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 2009; 34: 263271.
  • 143
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006; 27: 2431.
  • 144
    Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J. Psychiatr. Res. 1999; 33: 363370.
  • 145
    Valiengo LL, Soeiro-de-Souza MG, Marques AH et al. Plasma cortisol in first episode drug-naïve mania: Differential levels in euphoric versus irritable mood. J. Affect. Disord. 2012; 138: 149152.
  • 146
    Buoli M, Caldiroli A, Panza G, Altamura AC. Prominent clinical dimension, duration of illness and treatment response in schizophrenia. Psychiatry Invest. 2012; 9: 354360.
  • 147
    Abreu P, Llorente E, Hernández MM, González MC. Interleukin-1 beta stimulates tyrosine hydroxylase activity in the median eminence. Neuroreport 1994; 5: 13561358.
  • 148
    Shcherbakova IV, Siryachenko TM, Mazaeva NA, Kaleda VG, Krasnolobova SA, Klyushnik TP. Leukocyte elastase and autoanitbodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J. Biol. Psychiatry 2004; 5: 143148.
  • 149
    Silver H. Selective serotonin reuptake-inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin. Pharmacother. 2004; 5: 20532058.
  • 150
    Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 2011; 132: 96110.
  • 151
    Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology. Schizophr. Res. 2002; 57: 247258.
  • 152
    Fan X, Prostach C, Liu E, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007; 149: 267271.
  • 153
    Hilmas C, Pereira EF, Alkondon M et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 2001; 21: 74637473.
  • 154
    Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007; 93: 261265.
  • 155
    Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide. J. Psychiatr. Res. 2008; 42: 151157.
  • 156
    De Luca V, Tharmalingam S, Kennedy JL. Association study between the corticotrophin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur. Psychiatry 2007; 22: 282287.
  • 157
    Papiol S, Rosa A, Gutiérrez B et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J. Med. Genet. 2004; 41: 219223.
  • 158
    Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 2002; 17: 175179.
  • 159
    Hope S, Dieset I, Agartz I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res. 2011; 45: 16081616.
  • 160
    Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995; 29: 141152.
  • 161
    Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000; 33: 159164.
  • 162
    Kubera M, Maes M, Kenis G, Kim YK, Lasoń W. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005; 134: 251258.
  • 163
    Maes M, Bocchio Chiavetto L. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr. Res. 2002; 54: 281291.
  • 164
    Kim YK, Suh IB, Kim H. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs. Mol. Psychiatry 2002; 7: 11071114.
  • 165
    Igue R, Potvin S, Bah R et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog. Neuropsychopharmacol Biol. Psychiatry 2011; 35: 16951698.
  • 166
    Chaudhry IB, Hallak J, Husain N et al. Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012; 26: 11851193.
  • 167
    Stolk P, Souverein PC, Wilting I et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot. Essent. Fatty Acids 2010; 82: 914.